CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 141 enrolled
Drug / intervention
MCS110 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02807844
NCT02807844Phase 2Completed
CompareCT.gov

A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Novartis Pharmaceuticals·interventional·Posted Jun 21, 2016·Updated Aug 11, 2021

In Brief

A Phase 2 clinical trial evaluating MCS110 and PDR001 for Triple Negative Breast Cancer and 3 related conditions. Completed, enrolled 141 participants across 20 sites in 11 countries.

Detailed Summary

The purpose of this study of MCS110 with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriple Negative Breast Cancer, Pancreatic Carcinoma, Melanoma, Endometrial Carcinoma
CountriesBelgium, Finland, France, Germany, Hong Kong, Italy, Japan, South Korea, Spain, Switzerland, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 21, 2016
Enrollment StartJun 29, 2016
Primary CompletionJun 4, 2020
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 10.0 years ago

Interventions

MCS110drug

MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.

PDR001drug

MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.